Arthur A Vandenbark

This inventor holds 26 USPTO granted patents and 9 published patent applications and 1 EPO patent, primarily in Recombinant Proteins. Top assignees: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs, Connective Therapeutics, Inc.. Active years: 1997-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Arthur A Vandenbark. Retrieved from https://idiyas.com/inventor/arthur-a-vandenbark

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 9)

% Patents Active = 57.7

EPO Patents = 1 (Patent Applications = 9)

Average Co-Inventor Count = 2.1

ph-index = 7

Forward Citations = 285(Granted Patents)

Company Filing History:

22 out of 524

Oregon Health & Science University

patents

17 out of 958

The United States Government as Represented by the Department of Veterans Affairs

patents

1 out of 1

Connective Therapeutics, Inc.

patent

4. 1 out of 11

Connetics Corporation

patents

5. 1 out of 2,027

University System of Maryland

patents

6. 2 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...

Areas of Expertise:

Recombinant Polypeptides

MHC Class II

T-Cell Receptor Ligands

Autoimmune Disorders

Inflammatory Disorders

Prostate Cancer Vaccines

Cognitive Impairment

Molecule Detection

Antigen-Specific T-Cells

Therapeutic Use

Retinal Disorders

Immune-Related Disease

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11945855 - Recombinant polypeptides comprising modified MHC class II DRa1 domains and methods of use (2024-04-02),

2. 10689446 - Recombinant CD74 polypeptides (2020-06-23),

3. 10525101 - Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor (2020-01-07),

4. 10316075 - Recombinant polypeptides comprising MHC class II α1 domains (2019-06-11),

5. 9926360 - Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T-cells (2018-03-27),

6. 9492536 - Compositions and methods using recombinant MHC molecules for the treatment of stroke (2016-11-15),

7. 9359425 - Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction (2016-06-07),

8. 9260506 - Treatment of retinal disorders with recombinant T cell receptor ligand (RTL) (2016-02-16),

9. 9243051 - Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T-cells (2016-01-26),

10. 9050279 - Compositions and methods using recombinant MHC molecules for the treatment of stroke (2015-06-09),

11. 8895018 - Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction (2014-11-25),

12. 8685404 - Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction (2014-04-01),

13. 8491913 - Compositions and methods using recombinant MHC molecules for the treatment of stroke (2013-07-23),

14. 8435507 - Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer (2013-05-07),

15. 8377447 - Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells (2013-02-19),

Title: The Innovative Journey of Arthur A. Vandenbark

Introduction: Arthur A. Vandenbark, a pioneering inventor based in Portland, Oregon, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Arthur A. Vandenbark holds several patents in various technological domains, showcasing his continuous innovation and creativity in the industry.

Career Highlights: Throughout his illustrious career, Arthur A. Vandenbark has been recognized for his exceptional problem-solving skills and forward-thinking approach, leading to the development of cutting-edge technologies that have revolutionized the way we live and work.

Collaborations: Arthur A. Vandenbark has collaborated with leading research institutions, universities, and innovative companies to further his inventions and bring them to market, solidifying his reputation as a visionary inventor.

Conclusion: Arthur A. Vandenbark's dedication to innovation and his relentless pursuit of technological advancement have cemented his legacy as a trailblazer in the world of inventions, inspiring future generations of inventors to push the boundaries of what is possible.

Profile summary based on public USPTO records.